Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition containing orlistat and dihydropyrimidine compounds and use thereof

A technology of dihydropyrimidine and orlistat, applied in the field of biomedicine

Active Publication Date: 2021-07-13
ZHONGSHAN WANHAN PHARM CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, there is no technical revelation that the combined use of orlistat and dihydropyrimidines produces a synergistic inhibitory effect on HBV DNA replication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing orlistat and dihydropyrimidine compounds and use thereof
  • Composition containing orlistat and dihydropyrimidine compounds and use thereof
  • Composition containing orlistat and dihydropyrimidine compounds and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0060] Embodiment 2 Oral solid preparation containing MIX (x-OsT) and preparation method thereof

[0061] prescription

[0062]

[0063]

[0064] Tablet Preparation Method

[0065] Mix the prescribed amount of MIX (x-OsT) with 1 / 3 of the amount of starch, add 15% starch slurry (containing tartaric acid) to make a soft material for 10-15 minutes, or make wet granules with a 14-mesh sieve, and dry at 70°C , the dry granules are passed through a 12-mesh sieve, and then the granules are mixed with the remaining starch (pre-dried at 100-105°C) and talcum powder adsorbed with liquid paraffin, and then passed through a 12-mesh sieve. , compressed into tablets each weighing about 200mg.

[0066] Capsule preparation method

[0067] Mix the prescribed amount of MIX (x-OsT) with 1 / 3 of the amount of starch, add 15% starch slurry (containing tartaric acid) to make a soft material for 10-15 minutes, or make wet granules with a 14-mesh sieve, and dry at 70°C , the dry granule...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a composition containing orlistat and dihydropyrimidine compounds, and the specific definition of the dihydropyrimidine compounds is shown in the specification: the results of in vitro tests show that orlistat and the dihydropyrimidine compounds of the present invention The pyrimidine compounds can synergistically inhibit the replication of HBV DNA in Hep G2.2.15 cells within the stated molar ratio (combination index CI<1).

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a composition containing orlistat and dihydropyrimidine compounds and its application. Background technique [0002] Hepatitis B is a potentially fatal liver infectious disease caused by hepatitis B virus (HBV), which can increase the risk of death from liver cirrhosis and liver cancer. According to the World Health Organization (WHO), about 25.7 million people worldwide are infected with HBV, and a total of 887,000 people died of HBV in 2015, most of them died of HBV-induced diseases including liver cirrhosis and hepatocellular carcinoma. Therefore, HBV is a public health challenge faced by countries all over the world. Esser K et al found in the article Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an earlystep in the virus life cycle (source: Antiviral Res.2018Jan 5; 151:4-7.), lipase inhibitor weight loss drug orlistat He (orlistat) can p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61K31/506A61P31/20
CPCA61K31/365A61K31/506A61P31/20A61K2300/00
Inventor 李鉴有李翠玉黄海石吴彦勍杜志博彭韪
Owner ZHONGSHAN WANHAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com